Adult: As maintenance and prophylactic treatment: As metered dose inhaler: Mild to moderate cases: 50-200 mcg bid. Severe cases: Up to 400 mcg bid. Max: 800 mg daily. Doses are adjusted based on patient's clinical response and tolerability. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines). Child: ≥5 years As metered dose inhaler: 50 mcg bid. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
Nasal Allergic rhinitis, Non-allergic rhinitis
Adult: 1-2 sprays into each nostril bid. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
Oral Ulcerative colitis
Adult: For mild or moderate active-phase cases: As add-on therapy to 5-aminosalicylic acid (5-ASA) derivatives in patients who are unresponsive to 5-ASA therapy in active phase: 5 mg once daily for up to 4 weeks, given in the morning before or after a light breakfast.
Tubercular, local mycotic, and viral infections. Oral inhalation: Status asthmaticus, or other acute asthma episodes requiring intensive measures. Topical: Primary cutaneous viral infections (e.g. herpes simplex, chickenpox), varicose ulcers or any other stasis ulcers.
Special Precautions
Patient with tuberculosis, diabetes mellitus, gastroduodenal ulcer, serious arterial hypertension, osteoporosis, hypoadrenalism, glaucoma, cataract; intestinal infection, myasthenia gravis; current or history of severe affective disorders (including depression or manic-depressive illness and previous steroid psychosis); recent nasal septal ulcers, nasal surgery or trauma (nasal). Avoid exposure to chickenpox and measles. Not indicated for the relief of acute bronchospasm (inhalation). Avoid abrupt withdrawal. Renal and hepatic impairment. Pregnancy and lactation.
Adverse Reactions
Significant: Suppression of HPA axis (prolonged use), visual disturbance; psychiatric disturbances (e.g. depression, euphoria, insomnia, mood swings, personality changes); increased incidence of secondary infection, mask acute infection, prolong or exacerbate viral infections. Inhalation: Localised infections with Candida albicans, hypersensitivity reactions (e.g. urticaria, angioedema, rash, bronchospasm), reduction in growth velocity (in children); decrease in BMD, glaucoma, increased IOP, blurred vision, cataracts (prolonged use). Nasal: Nasal septal perforation. Topical: Local effects (e.g. skin atrophy, striae, burning, itching, irritation). Gastrointestinal disorders: Nausea, constipation, abdominal pain, diarrhoea. General disorders and administration site conditions: Influenza-like illness, pyrexia. Musculoskeletal and connective tissue disorders: Muscle cramps, back pain, myalgia. Nervous system disorders: Headache, somnolence. Psychiatric disorders: Anxiety. Reproductive system and breast disorders: Menorrhagia. Respiratory, thoracic and mediastinal disorders: Pharyngitis, voice disorder; nasopharyngitis, epistaxis (nasal). Potentially Fatal: Paradoxical bronchospasm (inhalation).
Oral inhalation: Monitor FEV1, peak flow and other pulmonary function test. Assess bone mineral density and growth. Monitor for signs and symptoms of HPA axis suppression, adrenal insufficiency, and oral candidiasis.
Action
Description: Mechanism of Action: Beclometasone is a synthetic corticosteroid which controls the rate of protein synthesis. It depresses the migration of polymorphonuclear leucocytes and fibroblasts. Additionally, it controls and prevents inflammation by reversing the capillary permeability and lysosomal stabilisation at the cellular level. Pharmacokinetics: Absorption: Readily absorbed from sites of local application. Bioavailability: Approx 20% (beclometasone-17-monopropionate). Time to peak plasma concentration: Oral: 4 hours (beclometasone-17-monopropionate). Inhalation: 2 minutes. Distribution: Rapidly distributed to all body tissues. Volume of distribution: 20 L. Plasma protein binding: Inhalation: 94-96% (beclometasone-17-monopropionate). Metabolism: Metabolised mainly in the liver and in other tissues including the lung and gastrointestinal tract via rapid hydrolysis by esterase enzymes into beclometasone-17-monopropionate (B-17-MP) (major active metabolite) and other minor metabolites (beclometasone-21-monopropionate and beclometasone). Excretion: Mainly via faeces (as metabolites); urine. Elimination half-life: 0.5 hours (oral); 4 hours (inhalation).
Chemical Structure
Beclometasone Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 20469, Beclomethasone. https://pubchem.ncbi.nlm.nih.gov/compound/Beclomethasone. Accessed May 27, 2025.
R03BA01 - beclometasone ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, glucocorticoids. R01AD01 - beclometasone ; Belongs to the class of topical corticosteroids used for prophylaxis and treatment of allergic rhinitis. D07AC15 - beclometasone ; Belongs to the class of potent (group III) corticosteroids. Used in the treatment of dermatological diseases. A07EA07 - beclometasone ; Belongs to the class of corticosteroids acting locally. Used in the treatment of intestinal inflammation.
References
AFT Pharmaceuticals Ltd. BecloClear 100 data sheet 22 August 2019. Medsafe. http://www.medsafe.govt.nz. Accessed 30/07/2024.Anon. Beclometasone Dipropionate (EENT). AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 01/10/2024.Anon. Beclometasone Dipropionate (Systemic). AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 01/10/2024.Arite Beclometasone 100 mcg/actuation Metered Dose Inhaler (Korta Pharma [M] Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 30/07/2024.Beclometasone (Nasal). UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 30/07/2024.Beclometasone (Oral Inhalation). UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 01/10/2024.Beclometasone (Systemic). UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 30/07/2024.Beclometasone (Topical). UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 01/10/2024.Beclometasone Dipropionate 0.25 mg/g Ointment (Chemidex Pharma Ltd). MHRA. https://products.mhra.gov.uk. Accessed 30/07/2024.Beconase Allergy; Beconase Hayfever (Omega Pharma Ltd.). MHRA. https://products.mhra.gov.uk. Accessed 30/07/2024.Beconase AQ (Stat Rx USA LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 30/07/2024.Brayfield A, Cadart C (eds). Beclometasone Dipropionate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 29/11/2024.Clipper 5 mg Gastro-resistant Prolonged Release Tablets (Chiesi Limited). MHRA. https://products.mhra.gov.uk. Accessed 30/07/2024.iNova Pharmaceuticals (New Zealand) Limited. QVAR 50 and 100 micrograms per Actuation Pressurised Inhalation Solution data sheet 27 July 2018. Medsafe. http://www.medsafe.govt.nz. Accessed 30/07/2024.Joint Formulary Committee. Beclometasone Dipropionate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 29/11/2024.QVAR Redihaler Aerosol, Metered (Teva Respiratory, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 30/07/2024.Soprobec 50 micrograms per Actuation Pressurised Inhalation Solution (Glenmark Pharmaceuticals Europe Limited). MHRA. https://products.mhra.gov.uk. Accessed 30/07/2024.
Sign Out
